Evidence map›Paper›PMID 28867115›Full record

ReviewPET clinics2017

Precision Medicine and PET/Computed Tomography in Melanoma.

Esther Mena, Yasemin Sanli, Charles Marcus, Rathan M Subramaniam

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PET clinics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. PET Imaging of Melanoma Using Melanin-Targeted Probe.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  5. Whole-Body versus Routine Skull Base to Mid-thighJournal of clinical imaging science · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Esther MenaMolecular Imaging Program, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room B3B402, Bethesda, MD 20892-1763, USA. Electronic address: esther.menagonzalez@nih.gov.
Yasemin SanliDepartment of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Charles MarcusThe Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21231, USA.
Rathan M SubramaniamDepartment of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Clinical Sciences, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Biomedical Engineering, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA.
The University of Texas Southwestern Medical Center · USJohns Hopkins University · USNational Institutes of Health · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.

Indexed as

Positron Emission Tomography Computed TomographyPrecision MedicineHumansMelanomaRadiopharmaceuticalsRadiopharmaceuticalsBiomarkerImmunotherapyMelanomaMolecular imagingPrecision oncologyTargeted therapy

Identifiers

PMID28867115
PMCPMC5701665
OpenAlexW2735678746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.